Author:
Richlitzki Cedric,Wiesweg Marcel,Metzenmacher Martin,Guberina Nika,Pöttgen Christoph,Hautzel Hubertus,Eberhardt Wilfried E. E.,Darwiche Kaid,Theegarten Dirk,Aigner Clemens,Bölükbas Servet,Schuler Martin,Stuschke Martin,Guberina Maja
Abstract
AbstractTo evaluate the prognostic value of biomarkers from peripheral blood obtained as routine laboratory assessment for overall survival in a cohort of stage III non-small cell lung cancer (NSCLC) patients treated with definitive radiochemotherapy at a high-volume cancer center. Seven blood biomarkers from 160 patients treated with definitive radiochemotherapy for stage III NSCLC were analyzed throughout the course treatment. Parameters were preselected using univariable and multivariable proportional hazards analysis and were assessed for internal validity using leave-one-out cross validation. Cross validated classifiers including biomarkers in addition to important clinical parameters were compared with classifiers containing the clinical parameters alone. An increased C-reactive protein (CRP) value in the final week of radiotherapy was found as a prognostic factor for overall survival, both as a continuous (HR 1.099 (1.038–1.164), p < 0.0012) as well as categorical variable splitting data at the median value of 1.2 mg/dl (HR 2.214 (1.388–3.531), p < 0.0008). In the multivariable analysis, the CRP value-maintained significance with an HR of 1.105 (1.040–1.173) and p-value of 0.0012. The cross validated classifier using CRP at the end of radiotherapy in addition to clinical parameters separated equally sized high and low risk groups more distinctly than a classifier containing the clinical parameters alone (HR = 2.786 (95% CI 1.686–4.605) vs. HR = 2.287 (95% CI 1.407–3.718)). Thus, the CRP value at the end of radiation therapy has successfully passed the crucial cross-validation test. The presented data on CRP levels suggests that inflammatory markers may become increasingly important during definitive radiochemotherapy, particularly with the growing utilization of immunotherapy as a consolidation therapy for stage III NSCLC.
Funder
Universitätsklinikum Essen
Publisher
Springer Science and Business Media LLC
Reference69 articles.
1. Ferlay, J. et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int. J. Cancer 136, E359-386 (2015).
2. Bradley, J. D. et al. Long-term results of nrg oncology RTOG 0617: standard- versus high-dose chemoradiotherapy with or without cetuximab for unresectable stage iii non-small-cell lung cancer. J. Clin. Oncol.: Offic. J. Am. Soc. Clin. Oncol. 38, 706–714 (2020).
3. Gray, J. E. et al. Three-year overall survival with durvalumab after chemoradiotherapy in stage III NSCLC-Update from PACIFIC. J. Thoracic Oncol.: Offic. Publ. Int. Assoc. Study Lung Cancer 15, 288–293 (2020).
4. Guberina, M. et al. Effectiveness of durvalumab consolidation in stage III non-small-cell lung cancer: focus on treatment selection and prognostic factors. Immunotherapy 14, 927–944 (2022).
5. Girard, N. et al. Treatment characteristics and real-world progression-free survival in patients with unresectable stage III NSCLC who received durvalumab after chemoradiotherapy: findings from the PACIFIC-R study. J. Thorac. Oncol. Offic. Publ. Int. Assoc. Study Lung Cancer 18, 181–193 (2023).